eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
5/2020
vol. 16
 
Share:
Share:
more
 
 
Hepatology
Experimental research

Evaluation of the mechanism of cordyceps polysaccharide action on rat acute liver failure

Lina Gu
1
,
Ting Yu
2
,
Jingyao Liu
3
,
Ying Lu
1

1.
Intensive Care Unit, the First Hospital of Jilin University, Changchun, China
2.
Department of Nutrition, the Second Hospital of Jilin University, Changchun, China
3.
Department of Neurology, the First Hospital of Jilin University, Changchun, China
Arch Med Sci 2020; 16 (5): 1218–1225
Online publish date: 2020/04/06
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Acute liver injury (ALF) is a liver injury syndrome with high lethality and mainly caused by a variety of liver diseases [1]. Liver cell transplantation is a new therapeutic tool to treat a variety of liver diseases; however, there are still several shortcomings limiting its application, low cell engraftment, and a short-lasting effect, due to which the patients tend to have a poor prognosis [2–5].
Cordyceps polysaccharide is the main active ingredient of Chinese caterpillar fungus, which not only plays a significant anti-tumor [6, 7], immunopotentiation [8], and anti-radiation [9] role but also has multiple protective effects on the liver [10, 11], such as decreasing circulating TNF- level and attenuating oxidative injury, possibly by reducing NOX activity and inhibiting ROS production in an LPS-induced acute liver model, and especially can be used as a good suppressive factor for transplant rejection [12, 13]. This study is based on the Chinese medical treatment strategy of liver diseases in which cordyceps polysaccharide was used as a treatment of ALF, whereas there is no domestic or international research on the action, and its mechanism, of cordyceps polysaccharide on ALF.

Material and methods

Animals

Sixty healthy 3-month-old male SPF SD rats, weighing 80–120 g, were purchased from the Experimental Animal Center of Sun Yat-sen University and housed at 20–28°C under constant humidity conditions with access to food and water ad libitum. The experiments were conducted 1 week later. All animal procedures were approved by the Institutional Animal Care and Use Committee of JiLin University, and the number of the Ethics Committee agreement is 2013-252.

Acute liver injury mouse model

Twelve rats were randomly chosen for group A (control), and the remaining rats were used to establish the ALF model and randomly divided into four groups (group B, C, D and E). The four experimental groups were injected intraperitoneally with 700 mg/kg D-galactosamine and 20 µg/kg lipopolysaccharide LPS [14], while the control group received normal saline only. Twenty-four hours later, groups C, D, E received cordyceps polysaccharide (Shanghai Biological Engineering Company, Shanghai, China) at the dose of 20 mg/ml, 10 mg/ml and 5 mg/ml respectively, and group B received isochoric normal saline. All the cordyceps polysaccharide was given with the method of gavage, once a day. All the rats in all five groups were divided into three groups randomly, and were sacrificed to obtain serum samples and livers at the first day, third day and seventh day. All rats had stomachs stuffed once a day. All of the experiments were approved by the Sun Yat-sen University Animal Ethics Committee.

Sample acquisition and processing

Blood samples and liver tissue samples were collected from all groups for assessing the liver function and cytokines, and stored at –80°C. The rats were euthanized, the abdominal cavity was cut layer-by-layer, the liver specimens were fixed with 4% poly-carboxylic acid, and histopathologic evaluation and protein detection were performed.

Histopathologic examination

Liver tissue specimens were harvested and fixed in 4% neutral a leaven 2–3 days. Stone vinegar was used for conventional embedment, section, and staining. The liver sections were visualized under light microscopy for morphologic analysis of pathologic changes.

Apoptosis detection

Liver specimens were collected from each group at the first day, third day and seventh day respectively, then fixed in paraformaldehyde and embedded in paraffin. Paraffin slices (4–6 µm) were dewaxed and flooded, and soaked in 3% H2O2 for 10 min at room temperature. The paraffin slices were washed with distilled water, digested with 200 U of freshly diluted trypsin K for 10 min at 37°C, and rinsed with 0.01 M Tris-buffered saline (TBS). Twenty microliters of a labeling buffer solution mixture (designated as the marking solution) was dripped onto each slice (1 µl of TdT, 1 µl of DIG-d-UTP, and 18 µl of labeling buffer solution). The slices were placed in a humidified chamber and incubated for 2 h at 37°C.
The slices were rinsed extensively with 0.01 M TBS, 50 µl of blocking solution was dropped onto each slice, incubated for 30 min at room temperature, then the blocking solution was removed. Dilute biotinylated digoxin (50 µl; 1 : 100 antibody dilution) was dropped onto the slices.
The slices were placed in a humidified chamber for 30 min at 37°C, rinsed with 0.01 MTBS, streptococcus avidin-biotin complex (SABC) antibody diluted 1 : 100, and mixed. Fifty microliters of dilute SABC was dropped onto each slice, reacted for 30 min at 37°C, then washed three times with 0.01 M TBS for 5 min each wash. The DAB color reaction was as follows: one drop of reagents A, B, and C from the DAB boxes into 1 ml of distilled water; mixed; dropped on the specimens; washed after the color reaction; and stained with hematoxylin. The specimens were transparently processed, mounted with neutral gum, and observed under an optical microscope; the apoptotic nuclei stained brown.

Western blot analysis

Liver tissue samples of each group were collected on day 7 and washed twice with PBS. Four hundred microliters of cell lysate were added to each bottle, then 40 µl of PMSF was added. The bottles were gently shaken to mix, and placed on ice for 10 min to allow uniform tissue lysis. Then, the liver specimens were repeatedly aspirated and dispensed with a sterile syringe, the lysate was placed in an EP tube on ice bathed for 30 min, and centrifuged at 12,000 g for 15 min. The serum supernatant was transferred into a new EP tube, 20 µl of protein sample buffer was added to every 100 µl of serum, boiled for 5 min, mixed evenly, and preserved at –80°C. The sample underwent separation on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) protein electrophoresis, the separated protein belts were transferred to PVDF membranes using the wet method, sealed under room temperature for 1 h, then the first antibodies (caspase-1, IL-18, IL-10, VEGF, and SDF-1 (all at a 1 : 1000 dilution)) purchased from BD Biosciences were added for overnight incubation at 4°C. After washing with Tris-buffered saline (TBS) or TBS-Tween, the membranes were incubated with the appropriate secondary antibody for 1 h at room temperature. Then, the second antibody was eluted, chemiluminescence was applied for color development and fixation, and the expression of caspase-1, IL-18, IL-10, vascular endothelial growth factor (VEGF), and stromal cell derived factor-1 (SDF-1) proteins was determined.

Enzyme-linked immunosorbent assay (ELISA)

Serum samples from each rat group were collected at the first day, third day and seventh day and detected for alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and DBIL with a commercial ELISA lit (Shanghai Biological Engineering Company). A standard sample dilution (0.5 ml) was added to lyophilized standard samples, dissolved for 15 min, mixed gently, and diluted as follows in pg/ml: 2000, 1000, 500, 250, 125, 62.5, 31.25, and 0. To the 80 µl standard sample dilution, 100 µl of sample was added and mixed with 10 µl of 1 N HCL. The specimen was placed for 60 min at 4°C, 10 µl of 1 N NaOH was added, and mixed. The slats were removed, a standard sample and sample dilution was added to blank holes, and the remaining corresponding holes were filled with standard samples of different densities. The holes were sealed with adhesive tape and placed at 37°C for 90 min. The concentrated biotinylated antibody was diluted into a 1 : 30 working solution, placed in the dark at room temperature, and the microplate was washed 5 times. An enzyme-conjugated dilution was added to the blank holes, and an enzyme-conjugated working solution was added to the remaining holes. The holes were sealed with new adhesive tape for the reaction, placed at 37°C for 30 min, and the microplate was washed 5 times. One hundred microliters of chromogenic substrate (TMB) was added per hole and placed in the dark at 37°C for 15 min. After adding the stop solution and mixing evenly, the OD450 value was immediately measured with a microplate reader (ELx800; BIO-TEK Company, England). The experiment was performed 3 times.

Synovial fluid PCNA and SIRP-α1 content detection using the PCR method

The liver tissues were removed and prepared as follows: 1 ml of Trizol reagent (BD Biosciences) was added to full cleavage; 0.2 ml of chloroform was added; the suspension was shaken; ice bathed for 5 min; centrifuged at 12,000 rpm for 20 min at 4°C; an equal volume of isopropanol was added to the suspension on ice for 5 min; centrifuged at 12,000 rpm for 20 min at 4°C; the supernatant was discarded; 1 ml of 75% ethanol was added; centrifuged at 10,000 rpm for 5 min at 4°C; the supernatant was removed; the EP tube was inverted; dried at room temperature for 15 min; 20 µl of RNase-free dd H2O was added to dissolve the sediment; 1 µl of lysate was absorbed and the remaining portion was placed in a –70°C refrigerator; the 1 ml lysate was diluted to 80 µl; the OD260 and OD280 were measured on a spectrophotometer; and the total RNA was calculated. Reverse-transcription reactions were performed using the SuperScript First-Strand Synthesis System (Sigma, St. Louis, MO, USA) as described previously [15]. Sample mRNA levels were semiquantified by RT-PCR or quantified by real time RT-PCR as previously described [16]. The proliferating cell nuclear antigen (PCNA), signal regulatory protein-1 (SIRP-1), and GAPDH gene sequences of the primers were as follows: PCNA, TCCCAGTTCACCATCCATGTC and GGTCCCCTAAGGCCCATTCCT; sIRP-1, ACAGATGAAGTGCTGCTTCC and GTCGGAGTTTCCTAGCTGGAT; and GAPDH, TCCTCCCATCAGCATCGCCC’ and ACACGCGGATGACGGGCA.

Statistical analysis

All results reported are representative of at least three separate experiments, and are expressed as mean ± SD. Between-group differences were analyzed using analysis of variance (ANOVA) and t-tests, with significance defined as p < 0.05.

Results

TUNEL staining of hepatic cells

Liver tissue apoptotic cells appeared after the first day. There were few liver tissue apoptotic cells in the normal group, but an abundance of liver tissue apoptotic cells in the model group; the difference was statistically significant. After the administration of medication, the number of apoptotic cells decreased in a dose-dependent manner (Figure 1).

Levels of ALT, AST, ALP, and TBIL

There were no significant differences of ALT, AST, ALP, and total bilirubin (TBIL) in the plasma of normal rats at the 3 time points (1, 3, and 7 days). The groups treated with cordyceps polysaccharide showed lower levels of ALT, AST, ALP, and TBIL in the plasma than the groups of ALF which only received the physiological saline (Figure 2). These results indicated that cordyceps polysaccharide can decrease the liver injury significantly, especially in a high dose.

Pathologic results

The control group showed diffuse necrosis of liver cells, hepatic cord dissociation, vague lobular structure, an abundance of bridging necrosis, a large number of lymphocytes infiltrated in the lobular and periportal areas, and edema and degeneration of residual liver cells at day seven. These findings suggest successful modeling of ALF, and the groups exposed to cordyceps polysaccharide showed a significant reduction of inflammatory cell infiltration, gradual lobular structure recovery, visible bile duct hyperplasia around the periportal area, and normal liver cells, especially in the high-dose group (Figure 3). Thus, the cordyceps polysaccharide with a high dose could improve the pathological features of ALF.

Expression level of caspase-1, IL-18, IL-10, VEGF, and SDF-1α protein in liver tissue

Based on Western blot analysis, the GAPDH protein belts were uniform in brightness, suggesting that the amounts of protein were basically the same in these samples. The groups exposed to medication showed lower expression levels of caspase-1, IL-18, and IL-10, but higher expression levels of VEGF, IL-10, and SDF-1 compared with the comparison group, especially in the group with high-dose medication (Figure 4). These results indicated that high-dose cordyceps polysaccharide could suppress the inflammation response in ALF.

Expression of PCNA and SIRP-α1 in rat liver tissues

In the normal group, the expression levels of PCNA and SIRP-1 were very low, which was significantly different from the model and pHGF groups. However, the expression level of SIRP-1 in the groups exposed to medication increased in a dose-dependent manner (Figure 5). These data suggested that high-dose of cordyceps polysaccharide could facilitate cell proliferation and liver regeneration.

Discussion

We established the rat ALF models by combining D-galactosamine with LPS, which has similar morphological features as human ALF, and analyzed the effects of cordyceps polysaccharide on rat liver function.
Serum ALT and AST levels were elevated, and the levels of caspase-1 and IL-18 in ALF rat liver tissues were significantly increased and higher in the model group compared with the control group. Liver function was more deteriorated and severe in group B than other groups [17], which indicated that caspase-1 and IL-18 may play a very important role in the pathogenesis of ALF, and also suggested that caspase-1 and IL-18 can serve as diagnostic and prognostic marker proteins for ALF [18–20]. After medication, the expression levels of caspase-1 and IL-18 in liver tissue improved gradually with the alleviation of liver inflammation. These results were clearly different in the high-dose medication group, suggesting that the medication effect is synergistic. The significant difference between medication and control groups at the third day and seventh day indicated that medication can decrease the level of caspase-1 and IL-18 by decreasing the systemic inflammatory response and inhibiting immune cell proliferation. Medication could regulate the equilibrium of pro- and anti-inflammatory factors, which may be an effective treatment for ALF. The variation in caspase-1 and IL-18 in the process of treatment also reflects the efficacy and prognosis of ALF.
Although the liver has a strong ability to regenerate, the lack of effective liver regeneration is still a major causal factor for lethality [21]. It has been reported that there is hope for survival when the hepatocyte remnants are more than 45%, and death due to liver failure is a certainty when less than 12% [22–24]. Therefore, it is of great importance to study the regeneration of liver cells in ALF. PCNA is a type of nuclear acidic protein that is closely related to cell proliferation, which could reflect the cell proliferation effectively [25–29]. SIRP-1, a negative regulatory factor, is involved in the entire process of liver regeneration [30], and participates in the regulatory process directly or indirectly with other positive or negative factors, especially in the termination of liver regeneration and proliferation, which may have important biological implications. Thus, cordyceps polysaccharide can effectively enhance the expression of PCNA and SIRP-1, and accelerate the regeneration of liver cells. However, there were still several limitations in our study. The three groups treated with cordyceps polysaccharide showed no significant difference in the levels of ALT, AST, ALP, and TBIL, and we did not perform in vitro experiments on the role of cordyceps polysaccharide.
In conclusion, cordyceps polysaccharide can also specifically home to the damaged liver, and promote the secretion of VEGF, hepatocyte proliferation, liver vascular regeneration, and liver tissue repair. Medication can reduce the level of IL-10, and regulate the balance of pro- and anti-inflammatory cytokines. Caspase-1 and IL-18 play an important role in the pathogenesis of liver failure and liver cell apoptosis. Medication also can reduce the levels of caspase-1 and IL-18, which are thought to be the predictors for ALF and future therapeutic targets. In summary, cordyceps polysaccharide can reduce the immune response and inflammatory injury in ALF and suppress liver cell apoptosis.

Conflict of interest

The authors declare no conflict of interest.
Copyright: © 2020 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe